New liver toxicity testing solution for drug development

15 March 2011

ToxInsight DILI Assay Cartridge, claimed to be a groundbreaking new tool for assessing the liver toxicity risk of chemical compounds, has been introduced by US firm Thermo Fisher Scientific, which is debuting its product at the 2011 Society of Toxicology & ToxExpo, Washington DC.

It will help pharmaceutical companies improve their productivity by better assessing liver toxicity early in the drug development process, specifically reducing the risk of drug-induced liver injury (DILI) - the primary reason for post-market drug withdrawal, the firm noted.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical